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Abstract
Ovarian cancers mostly arise sporadically, however about 20–25% of the cases 
arise as a part of hereditary syndromes. There are numerous mutations involved in 
the ovarian cancer development and more to be discovered. Knowing the patho-
genic variants of the mutations present in the ovarian cancers are important in 
developing and practising of risk reduction strategies in asymptomatic carriers, 
genetic counselling, prognostication and decision on treatment. This chapter will 
focus on the various types of mutations found in ovarian cancers and their implica-
tions- when considering testing, treatment options and insight for the next level of 
Improvement in cancer care.
Keywords: ovarian cancer, somatic BRCA mutation, germline BRCA mutations, 
PARP inhibitors, homologous recombination
1. Introduction
BRCA1/2 somatic and germline, PTEN deletion, CCNE amplification and RB1/NF1 
loss, RAD51C, RAD51D, BRIP 1 are some of the known mutations causing the ovarian 
cancers [1]; the BRCA1/2 gene mutations are the most common and deleterious to find 
in this spectrum. From women who inherit a pathogenic BRCA1 variant and BRCA2 
variant at risk of developing ovarian cancer 39–44% and 11–17% respectively by the 
age of 70–80 years [2, 3].
The current recommended guidelines for all high grade serous ovarian cancer 
patients at the diagnosis, apart from mucinous adenocarcinoma of Ovaries, are 
screen upfront for pathogenic BRCA1/2 genes, regardless whether they have 
family history or not. The uptake of this screen is 1:10 patient, and if we extend 
the screening to tumour somatic testing, the uptake becomes 17% of all ovar-
ian cancer diagnosis with germline and somatic BRCA mutations. Difference 
between the somatic and the germline BRCA mutations are discussed later in this 
chapter.
The following is a schematic representation of the various known mutation 
prevalence in the ovarian Cancers particularly in High grade serous ovarian car-
cinoma. As obvious BRCA1 and BRCA2 are the most common type of mutations 
found in the OC and signifies the importance, hence this chapter mainly focus on 
the BRCA mutations (Figure 1).
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2. Genetics of sporadic ovarian cancers
There’s a multitude of genetics involved in the sporadic ovarian cancers, involv-
ing multiple cellular pathways. There are 2 types of sporadic ovarian cancers 
according to their behaviour, histology, genetic according to Kurman and shih’s 
original article “The origin and pathogenesis of epithelial ovarian cancer: a pro-
posed unifying theory”, type 1 and type 2 [4]. Type1 tumours are slow growing, 
indolent tumours and Type 2 being high grade, aggressive.
Some of the mutations associated with sporadic type1 ovarian cancers are KRAS, 
BRAF, ERBB2, PIK3CA, ARID1A, CTNNB1 and PTEN. In normal cells these genes and 
their products will regulate the cell growth, chromatin remodelling, DNA repair, cellular 
proliferation and controlling of apoptosis preventing tumour development. Mutations in 
these genes inevitably causes increases susceptibility to development of malignancies [4].
Type 2 sporadic ovarian cancers which are high grade share the similar genetics 
as hereditary ovarian cancers TP53, BRCA1 and BRCA2 [4].
3. Genetics of hereditary OC
Hereditary Breast ovarian cancer syndrome, Lynch Syndrome, Li-Fraumani, 
Cowden and Peutz-jeghers syndrome are some of the few of Hereditary ovar-
ian cancer syndromes, all of which inherit in autosomal dominant pattern [5, 6]. 
Patients who presents at young age, multiple primaries and/or a high incidence of 
family history of malignancy should be considered as having hereditary OC and 
should be investigated for the genetic mutations. Eighty percent [80%] of this type 
of ovarian cancers are associated with BRCA1/2 gene mutation and minority are 
with RAD51C, RAD51D, BRIP1, PALB2, BARD1, NBN and MRE11A.
4. BRCA1/2 gene structure and functions
BRCA1 and BRCA2 genes were discovered in early nineties following extensive 
research on breast cancer patients and families, hence the name Breast cancer 
susceptibility gene [BRCA] and identified as responsible in the ovarian cancer 
Figure 1. 
Common Pathogenic mutations in high grade serous ovarian cancer. 
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causation as well. BRCA1 and BRCA2 pathogenic mutations are found in 10–15% of 
sporadic ovarian cancers and about 40% of Hereditary ovarian cancers [7].
These genes are tumour suppressor genes encode for tumour suppressor pro-
teins, which will help in maintaining genomic stability. BRCA1 and BRCA2 are 
large genes contain about 100–70 Kilo bases respectively. BRCA1 situated in long 
arm of chromosome 17 at 17q21 position and BRCA2 gene is in chromosome 13 at 
13q12.These 2 genes encode for different protein structures although still have got 
functional similarities [8]. BRCA1 protein consists of nuclear localization sequence 
(NLS) and three functional domains; RING, coiled coil, and BRCT domains, 
whereas BRCA2 protein has NLS, eight BRC repeats, and a DNA binding domain.
BRCA1 and BRCA2 genes helps in repairing the double strand breakage in DNA 
by promoting the homologous recombination, which is a highly accurate process in 
the maintenance of genomic stability and regulating the cell cycle and apoptosis.
5.  Action of BRCA1 and BRCA2 proteins in DNA double strand damage 
repair
Although the action of the BRCA1 and BRCA2 gene products in cancer causation 
is not fully discovered [9], their function in maintaining the genomic stability is well 
understood. This involves the DNA double strand break repair [DSB] which is the 
most deleterious type of DNA damage as no healthy DNA strand left for the repair 
mechanism [10]. The DSB will be repaired by 2 mechanisms in the healthy eukaryotic 
cells -The Homologous directed repair [HDR] pathway, which is a highly accurate 
system and Non-Homologous end joining [NHEJ] pathway which is prone to errors. 
BRCA1 and BRCA2 proteins involve in the HDR mechanism following stimulated 
by the cellular DNA damage response. This function is facilitated by other cellular 
proteins including RAD51 [11, 12], Ataxia-Telangiectasia kinase [ATM-kinase].
The following flow chart shows the mechanism of DNA DSB repair and the steps 
involving the BRCA1/2 proteins (Figure 2).
Mutation of the BRCA1/2 genes causing loss of the encoded protein func-
tions causes abnormal checkpoint stimulation and genomic errors in DNA repair 
Figure 2. 
Action of BRCA1/2 protein in DNA double strand break repair. Source - functions of BRCA1 and BRCA2 in 
the biological response to DNA damage [13].
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causing cancer development through uncontrolled cellular proliferation, impaired 
cell apoptosis in abnormal cells.
6. Somatic vs. germline BRCA mutations
BRCA1/2 mutations can occur in the germline causing the hereditary susceptibil-
ity to ovarian and other types of cancers. There are BRCA mutations can occur in the 
somatic cells as well -within the tumour itself which consists of 3% of whole BRCA 
mutation found in the high grade serous ovarian cancers, without mutation in the germ-
line. Presence of germline BRCA mutation gives rise to specific behaviour of the ovarian 
cancer, response to treatment and the prognosis. Patients with germline BRCA muta-
tions will develop cancers at young age, commonly have visceral disease at presentation 
and shows high sensitivity to platinum-based chemotherapy and PARP inhibitors.
Clear relationship between the somatic BRCA mutations and the features of the 
response to the treatment and the clinical features are yet to be identified [14].
7. Implications of BRCA testing in ovarian cancer
Currently there’s no proven benefit of population screening for sporadic ovarian 
cancer as the trial results are still pending to show reduction in the mortality and 
survival benefit from the early screening of asymptomatic patients in this category. 
However screening strategies in hereditary ovarian cancers are important for the 
prophylactic procedures such as bilateral Salpingo-oophorectomy which can reduce 
the risk of development of cancer by 79% in endometrium, fallopian tube, ovaries 
which has been proven by meta-analysis.
8. Testing for germline BRCA mutations in ovarian cancer patients
Genetic testing for germline-BRCA1/BRCA2 mutations in epithelial ovarian 
cancer (EOC) was commissioned by National Health Service England in 2015 [15]. 
In the United Kingdom, all genetic counselling take place in Cancer Centres, and all 
first degree family member will be given a letter to inform them of the risk in them 
carrying this gene and a mean to have germline BRCA status tested on the NHS. The 
NHS will also provide risk reduction surgery to prophylactic Breast and Ovarian 
surgery once the family planning is completed and the decision made by affected 
family members. For those who do not wish to embark on these prophylactic surger-
ies, there are guidelines for surveillance with Mammograms and blood test Ca 125 
for the affected gene mutation carriers. For male gene carriers, there are now early 
PSA surveillance available for General physician to follow.
Germline BRCA testing is done via a blood test following gaining the consent of 
the patient, according to the NCCP [National cancer control programme] guide-
lines, which is then being sent to the Cancer Molecular Diagnostics Laboratory.
9. Testing for somatic BRCA mutations in ovarian cancer patients
Testing for somatic BRCA mutation was introduced in October 2020 in UK. 
The samples from the previous biopsy or surgery including the ovarian cancer 
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tissue block/slides are needed for somatic BRCA mutation testing. The block must 
be of reasonable quality, neoplastic cell content >50% included. This should be 
sent at room temperature with a copy of the block(s) histopathology report within 
5  working days of patient registration.
Although the germline BRCA testing could be a straightforward blood test, 
the somatic BRCA mutation comes with some challenges, which are summarised  
below.
1. Issues with extracting high quality DNA samples from the preserved tumour 
samples-which needs tumour microdissection, so that a small tumour 
samples will not be enough for the purpose. Also poor fixation samples can 
cause fragmented and damaged DNA and also formalin used in fixation can 
cause deamination of the nucleic acids leading to sequencing errors and false 
mutations.
2. Analysis and interpretation of sequencing data as there is currently no 
 standardised interpretation.
3. The stability of the somatic BRCA mutations can change over time due to can-
cer selection, resistance, treatment and within the tumour itself due to hetero-
geneity of the tumour cells.
For most countries the method for detecting the BRCA mutation still limited to 
one or the other due to funding issues.
10. The significance of BRCA mutation in HGSOC
As mentioned earlier in the chapter being positive for BRCA mutations when 
compared with the wild type, gives the ovarian cancer specific features – impor-
tantly higher response rate to platinum and other types of non-platinum chemo-
therapeutic agents [16] and more importantly high sensitivity to Poly(ADP-ribose) 
polymerase (PARP) inhibitors, which is highly important as a maintenance therapy 
of the patients who have responded to first line platinum based chemotherapy in 
improving 5 year disease free survival.
11. What are PARP inhibitors?
Poly (ADP-ribose) polymerase (PARP) is a protein mediated the DNA double 
strand break repair, which was first identified in early sixties and first PARP inhibi-
tor was discovered in 1980 as a chemotherapy sensitizer [17].
Following figure illustrates the normal action of the PARP proteins to aid the 
understanding of how the PARP inhibitors work (Figure 3).
In 2005 and 2006, inhibiting PARP enzymes was first observed to be highly 
effective against cancers with homologous recombination deficiencies [19], are 
being utilised in the clinical setting to manage recurrent ovarian cancers. However, 
PARPi – Niraparib also show significant clinical benefit in patients without HR 
deficiencies [20]. There are currently three FDA-approved PARP inhibitors for 
recurrent ovarian cancer – Olaparib, Rucaparib and Niraparib.
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12. PARP inhibitors in the treatment of ovarian cancers
Since the discovery in 1980 s PARP inhibitors has gone through extensive 
 scrutiny and research in the efficiency in management of the ovarian cancers.
The initial monotherapy with PARP inhibitors for patients with solid tumours 
with a germline BRCA mutation were published in 2009. This was a study on ovar-
ian cancer patients with known BRCA mutation [21]. Other tumours included were 
breast, colon, melanoma, prostate, and sarcomas. In patients with known BRCA1/2 
mutations, single-agent treatment with Olaparib showed a 63% clinical benefit 
(including disease stabilisation).
Following this study there several other trials carried out for assessing the 
individual efficacy of the Olaparib, Niraparib and Rucaparib and with the outcomes 
of these trials Olaparib has gained the FDA approval as a first line maintenance 
treatment in the advanced ovarian cancer [22].
Figure 3. 
Function of PARP proteins in DNA damage repair. Source: An update on PARP inhibitors—Moving to the 
adjuvant setting [18].
Trial name PARPi assessed vs. 





Niraparib vs. Placebo Stage III with visible residual tumour after PDS, 
inoperable stage III, or any stage IV ovarian cancer.
SOLO-1 Olaparib vs. Placebo BRCA1/2 mutated, CR or PR (≥30% decrease 
in tumour volume, or NED on imaging but 




Olaparib + bevacizumab vs. 
placebo + bevacizumab
Newly diagnosed stage III/IV high-grade ovarian 
cancer or other non-mucinous ovarian cancers with 
BRCA1/2 mutation, regardless of surgical outcome




Veliparib + CP → veliparib 
vs. veliparib + CP → placebo 
a vs. placebo + CP → placebo
Newly diagnosed stage III/IV high-grade serous 
ovarian cancer in patients undergoing PDS or IDS
Key PDS - Primary debulking surgery, CR - complete response, PR - Partial response, IDS - interval debulking 
surgery, NED - no evidence of disease, C - Carboplatin, P - Paclitaxel.
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The following is a summary of the trials on PARP inhibitors and the SOLO-1 trial 
being of the pivotal trials in the history of the use of PARP inhibitors [23].
13. Current UK standards for testing ovarian cancer genetics
According to current British Gynaecological Cancer Society guidelines for test-
ing ovarian cancer genetics,
Women with High grade serous ovarian cancer or G3 endometrioid ovarian adeno-
carcinoma have >10% risk of an underlying BRCA mutation should be offered clinical 
genetics counselling and testing. (GRADE C) Recently it has been shown that ~18% 
(much higher in certain groups such as Ashkenazi Jews) of the population of women 
presenting with high grade serous or G3 endometrioid ovarian adenocarcinoma carry a 
germline BRCA mutation, 44% of whom have no positive family history. Every patient 
with a current or past histological diagnosis of HGSC or G3 endometrioid ovarian 
carcinoma therefore qualifies for BRCA counselling and testing, as advised by National 
institute for Health and Care Excellence, which should be discussed and offered.
The above guidelines and standards are supported by the evidence from the 
GTEOC (Genetic Testing in Epithelial Ovarian Cancer) [24] study in which the 
primary objective of the study was to determine the feasibility, acceptability and 
cost-effectiveness of screening all newly diagnosed women with EOC for BRCA1/
BRCA2 mutations by determining the mutation prevalence, calculating the cost 
for each gene mutation detected and assessing the psychological impact based on 
questionnaire responses and qualitative interviews.
This study has shown the mutation yield in unselected women diagnosed 
with EOC from a heterogeneous population with no founder mutations was 8% in 
all ages and 12% in women under 70 [25]. Unselected genetic testing in women with 
EOC was acceptable to patients and is potentially less resource intensive.
14.  Challenges in development of universal process on screening genetic 
mutations in ovarian cancers
In Our Opinion, all the patients diagnosed with invasive, epithelial ovarian cancer 
should be offered germline genetic testing, regardless of histologic subtype, because 
Ovarian cancers with a BRCA1/BRCA2 mutation are most likely to be of high-grade 
serous histology, although these mutations have been found in endometrioid and clear 
cell histologic subtypes as well. Endometrioid and clear cell ovarian cancers are also 
frequently associated with Lynch syndrome (germline mutations in MLH1, MSH2, 
MSH6, PMS2, and EPCAM). Additionally, nonepithelial ovarian cancers - Sertoli-
Leydig cell tumours can be associated with other genetic disorders such as Peutz-
Jeghers syndrome and DICER1-associated disorders and small cell carcinoma of the 
ovary, hypercalcaemic type has been linked to germline mutations in SMARCA4.
All these mutations have got clinical relevance in the management of these 
patients and yet to discover the treatment options and preventing the development 
of the other cancer types associated with the above syndromes in the future genera-
tions with genetic predisposition.
There are several identified limitations in screening these mutations including cost of 
testing, lack of patient and provider education regarding the importance of genetic infor-
mation, and limited availability of genetic counsellors and access to genetic testing [26].
In the era of unforeseen issues with Covid-19 there are other issues with genetic 
testing including social distancing making the genetic counselling, consenting 
difficult necessitating these steps to be delivered audio-visually.
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15. In summary
There are numerous types of genetic mutations causing sporadic and hereditary 
ovarian cancers and more to be discovered yet. These mutations cause genomic 
instability in turn leading to cancer causation. Having a certain type of mutation 
will gives rise to clinically specific type of ovarian cancer, with different response to 
treatment, prognosis and predictability in behaviour.
Early identification of these mutations, genetic counselling will optimise the 
patient outcome, prevention of the ovarian and other genetically predisposed 
cancers in next generations.
Developing a universal testing pathway which is cost effective, is still challeng-
ing due to various factors.
The arrival of personalising treatment with Molecular typing of Ovarian 
Cancer has revolutionised maintenance therapy in Ovarian Cancer that has never 
seen before. Not only we are routinely screening for germline and somatic BRCA 
mutation upfront in all newly diagnosed Ovarian Cancer, we increasingly modify 
our treatment paradigm by providing PARPi in DNA mismatch repair deficiency 
detected patients. This extends from just BRCA mutation to the other Homologous 
recombinant deficiency genes as delineated in Figure 1. In 2020, FDA approved of 
MEK-inhibitor, Trametinib for Low grade Ovarian Cancer. And soon to be NICE 
guidelines for routine screening for Microsatellite instability genes, MMR MSI in all 
Endometrial Cancer, in search for 40% incidence of MSI MMR deficiency.
In 2021 November, with the sentinel FDA approval for liquid biopsy testing in 
solid cancers, which was predominantly based on detection of BRCA genes and 
most HRD genes, this has solid foundation in one test for defective molecular mark-
ers in blood, hopefully well before development of Cancer, for our exciting future 
to come.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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